Żok J, Bieńkowski M, Radecka B, et al. - Researchers assessed the association between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence in patients suffering from stage III colon cancer (CC). Participants were 365 patients who had received treatment at five oncology centers in Poland between 2000 and 2014. In 130 patients (37.8%), occurrence of early recurrence < 36 months post-surgery was documented. An elevated risk of early recurrence within 18 months of surgery was observed in relation to RDI-O < 60% in adjuvant therapy among stage III CC (particularly in low-risk group). Findings revealed worse overall survival in patients with early recurrence, irrespective of the RDI-O.